|1.||Mori, Akihisa: 10 articles (11/2015 - 03/2008)|
|2.||Jenner, Peter: 5 articles (11/2015 - 06/2005)|
|3.||Mori, A: 5 articles (01/2010 - 06/2008)|
|4.||Kanda, Tomoyuki: 4 articles (11/2015 - 01/2014)|
|5.||Chaikin, Philip: 4 articles (10/2012 - 03/2008)|
|6.||Sussman, Neil M: 4 articles (07/2010 - 09/2007)|
|7.||Kawai-Uchida, Mika: 3 articles (11/2015 - 01/2014)|
|8.||Japanese Istradefylline Study Group: 3 articles (03/2015 - 07/2010)|
|9.||Kondo, Tomoyoshi: 3 articles (03/2015 - 07/2010)|
|10.||Mizuno, Yoshikuni: 3 articles (03/2015 - 07/2010)|
|1.||Parkinson Disease (Parkinson's Disease)
01/15/2013 - "The result showed a significant reduction of the awake time per day spent in the OFF state and improvement of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III in the ON state when receiving istradefylline compared with patients receiving placebo. "
07/30/2010 - "Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study."
11/01/2015 - "Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial."
03/01/2015 - "A long-term study of istradefylline safety and efficacy in patients with Parkinson disease."
02/01/2012 - "Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study."
11/05/2015 - "These results show that istradefylline is effective in improving motor function in combination with low dose dopaminergic drug treatment without provoking dyskinesia. "
02/01/2012 - "In Phase 2b/3 studies, Istradefylline reduced OFF time without worsening troublesome dyskinesia and was well tolerated. "
08/12/2003 - "This was a 12-week, double-blind, randomized, placebo-controlled, exploratory study in which PD subjects with both motor fluctuations and peak-dose dyskinesias were randomized to treatment with placebo (n = 29), istradefylline up to 20 mg/day (n = 26), or istradefylline up to 40 mg/day (n = 28). "
01/15/2015 - "Administration of istradefylline (10mg/kg p.o.) alone resulted in a decrease in motor disability and increase in 'ON' time but dyskinesia was not observed. "
07/01/2013 - "The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%). "
01/01/2008 - "KW 6002 and MSX-3 suppressed pimozide-induced tremulous jaw movements, reduced catalepsy, and increased locomotion. "
11/01/1999 - "The ED50s of KW-6002 in the reversal of CGS21680-induced and reserpine-induced catalepsy were 0.05 mg/kg, PO and 0.26 mg/kg, PO, respectively. "
11/01/1999 - "Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP."
11/01/1999 - "We evaluated the efficacy and potency of KW-6002 and other reference compounds in the selective adenosine A2A receptor agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosin e (CGS 21680)-, haloperidol- or reserpine-induced catalepsy models. "
11/01/1999 - "Combined administrations of subthreshold doses of KW-6002 and L-dopa (50 mg/kg, PO) exerted prominent effects on haloperidol-induced and reserpine-induced catalepsy, suggesting that there may be a synergism between the adenosine A2A receptor antagonist KW-6002 and dopaminergic agents. "
07/01/2014 - "Acute, as well as chronic, oral administration of istradefylline significantly improved the inescapable shock (IES)-induced escape deficit with a degree of efficacy comparable to chronic treatment with the tricyclic antidepressant desipramine and the selective serotonin (5-HT) reuptake inhibitor, fluoxetine. "
|5.||Memory Disorders (Memory Loss)
11/01/2007 - "ASP5854 ameliorated A(2A) agonist 2-[p-(2-carboxyethyl) phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the minimum effective doses of 0.32 and 0.1 mg/kg, respectively, and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg. In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated l-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg. ASP5854 also significantly restored the striatal dopamine content reduced by 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg. Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A(2A) antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not. "
|1.||Levodopa (L Dopa)
|2.||Adenosine A2A Receptor (Adenosine A2A Receptors)
|6.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|9.||Caffeine (No Doz)